| Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors N Yamamoto, H Nokihara, Y Yamada, T Shibata, Y Tamura, Y Seki, ... Investigational new drugs 35, 207-216, 2017 | 82 | 2017 |
| Prospective survey of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer K Honda, B Gyawali, M Ando, R Kumanishi, K Kato, K Sugiyama, S Mitani, ... Journal of global oncology 5, 1-8, 2019 | 66 | 2019 |
| A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors S Nakamichi, H Nokihara, N Yamamoto, Y Yamada, K Honda, Y Tamura, ... Cancer Chemotherapy and Pharmacology 76, 1153-1161, 2015 | 49 | 2015 |
| Muscle wasting associated with the long-term use of mTOR inhibitors B Gyawali, T Shimokata, K Honda, C Kondoh, N Hayashi, Y Yoshino, ... Molecular and clinical oncology 5 (5), 641-646, 2016 | 47 | 2016 |
| Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study H Asahina, H Nokihara, N Yamamoto, Y Yamada, Y Tamura, K Honda, ... Investigational new drugs 31, 677-684, 2013 | 45 | 2013 |
| Baseline sarcopenia and skeletal muscle loss during chemotherapy affect survival outcomes in metastatic gastric cancer K Sugiyama, Y Narita, S Mitani, K Honda, T Masuishi, H Taniguchi, ... Anticancer Research 38 (10), 5859-5866, 2018 | 44 | 2018 |
| A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study K Honda, B Gyawali, M Ando, K Sugiyama, S Mitani, T Masuishi, Y Narita, ... Ecancermedicalscience 12, 2018 | 40 | 2018 |
| Chemotherapy in locally advanced head and neck squamous cell carcinoma B Gyawali, T Shimokata, K Honda, Y Ando Cancer treatment reviews 44, 10-16, 2016 | 39 | 2016 |
| Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report K Honda, S Kadowaki, K Kato, N Hanai, Y Hasegawa, Y Yatabe, K Muro Investigational New Drugs 37, 791-795, 2019 | 37 | 2019 |
| Opioid-induced constipation B Gyawali, N Hayashi, H Tsukuura, K Honda, T Shimokata, Y Ando Scandinavian journal of gastroenterology 50 (11), 1331-1338, 2015 | 36 | 2015 |
| FOLFOX as first-line therapy for gastric cancer with severe peritoneal metastasis T Masuishi, S Kadowaki, M Kondo, A Komori, K Sugiyama, S Mitani, ... Anticancer Research 37 (12), 7037-7042, 2017 | 35 | 2017 |
| Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors K Honda, N Yamamoto, H Nokihara, Y Tamura, H Asahina, Y Yamada, ... Cancer chemotherapy and pharmacology 72, 577-584, 2013 | 34 | 2013 |
| Reporting harms more transparently in trials of cancer drugs B Gyawali, T Shimokata, K Honda, Y Ando BMJ 363, 2018 | 31 | 2018 |
| Should low-income countries invest in breast cancer screening? B Gyawali, T Shimokata, K Honda, H Tsukuura, Y Ando Cancer Causes & Control 27, 1341-1345, 2016 | 30 | 2016 |
| Common Sense Oncology: outcomes that matter CM Booth, M Sengar, A Goodman, B Wilson, A Aggarwal, S Berry, ... The Lancet Oncology 24 (8), 833-835, 2023 | 29 | 2023 |
| Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer K Honda, K Takeshita, K Murotani, A Mitsuma, H Hayashi, N Tsunoda, ... Breast Cancer 24, 312-318, 2017 | 23 | 2017 |
| Efficacy of cytotoxic agents after progression on anti-PD-(L) 1 antibody for pre-treated metastatic gastric cancer K Kato, Y Narita, S Mitani, K Honda, T Masuishi, H Taniguchi, S Kadowaki, ... Anticancer Research 40 (4), 2247-2255, 2020 | 19 | 2020 |
| Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials B Gyawali, T Shimokata, M Ando, K Honda, Y Ando Annals of Oncology 28 (2), 246-253, 2017 | 18 | 2017 |
| The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation S Mitani, H Taniguchi, K Sugiyama, T Masuishi, K Honda, Y Narita, ... Therapeutic advances in medical oncology 11, 1758835918820298, 2019 | 15 | 2019 |
| Site-specific chemotherapy based on predicted primary site by pathological profile for carcinoma of unknown primary site H Hasegawa, M Ando, Y Yatabe, S Mitani, K Honda, T Masuishi, Y Narita, ... Clinical Oncology 30 (10), 667-673, 2018 | 12 | 2018 |
